

OCT 30 2007

PTO/SB/08A (10-07)

Approved for use through 10/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 5

Application Number	10/733,489
Filing Date	December 10, 2003
First Named Inventor	Yaron Ilan
Art Unit	1648
Examiner Name	Emily M. Le
Attorney Docket Number	Enz-64(D1)

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US- 08/808,629	02-28-1997	Roy-Chowdhury et al.	
	2	US- 10/377,628	03-04-2003	Roy-Chowdhury et al.	
	3	US- 10/377,603	03-04-2003	Roy-Chowdhury et al.	
	4	US- 09/447,704	02-28-1997	Roy-Chowdhury et al.	
	5	US- 09/356,294	07-16-1999	Roy-Chowdhury et al.	
	6	US- 10/385,440	05-09-2001	Roy-Chowdhury et al.	
	7	US- 2003/0170258	09-11-2003	Roy-Chowdhury et al.	
	8	US- 10/451,811	06-25-2003	Ilan et al.	
	9	US- 10/375,906	02-27-2003	Ilan et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	* ⁶
	10	WO 25/051986	12-24-2001	Ilan et al.		

Examiner Signature	/E.L./	Date Considered	06/09/2008
--------------------	--------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard 3.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard 3.16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Approved for use through 10/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Application Number	10/733,489
Filing Date	December 10, 2003
First Named Inventor	Yaron Ilan
Art Unit	1648
Examiner Name	Emily M. Le
Attorney Docket Number	ENZ-64(D1)

Sheet	2	of	5
-------	---	----	---

[illegible]

Examiner Signature	/E.L./	Date Considered	06/09/2008
-----------------------	--------	--------------------	------------

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the burden of this collection of information should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22314-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22314-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 3 of 5

Application No. 10/733,489

Filing Date: December 10, 2003

First Named Inventor: Ilan et al.

Art Unit: 1648

Examiner Name: Emily M. Le

Attorney Docket Number: Enz-64(D1)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city and/or country where published	T ²
	11	Dwek, RA., Block, TM, Nichita-Branza, N., Petrescu, S., Platt, F., Rudd, PM, Zitzmann, N., " Abnormal glycosylation in disease and therapy ", Proceedings of the Royal Society of Medicine's 5 th Jenner Symposium (Glycobiology and Medicine conference), July 10-11, 2000	
	12	Axford Glycobiology & Medicine: A millennial Review, July 2000	
	13	Margalit et al. Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes. Am. J. Physiol. Gastrointest. Liver Physiol., November 2005, Abstract	
	14	Margalit et al. Amelioration of hepatic fibrosis via beta-glucoceramide mediated immune modulation is associated with NKT lymphocyte distribution and a cytokine shift. Am. Assoc. For Study of Liver Diseases, Meeting, November 2005	
	15	Margalit et al. Suppression of hepatocellular carcinoma by glucocerebroside is associated with altered NKT and CD8+ lymphocyte distributions, stat1 expression, lack of stat6 expression and a Th1 type immune response. Am Assoc. For Disease of Liver, October 200, Abstract	
	16	Zigmond et al., Facilitation of hepatocellular carcinoma growth in mice by double negative NKT regulatory lymphocytes is inhibited by ex vivo exposure to beta-glucosylceramide. Am Assoc. for Study of Liver Diseases, Meeting, November 2005	
	17	Knipe, DM, Howley, PM, eds. Fields virology. 4 th ed. Vol. 1. Philadelphia: Lippincott Williams & Wilkins, 2001, 1004-1016 and 1127-1161	
	18	Hahn. Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Current opinion in immunology, 2003, Vol.15, 443-449	
	19	De Francesco et al., Challenges and successes in developing new therapies of hepatitis C. Nature, 2005, Vol. 436, 953-960	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 4 of 5

Application No. 10/733,489

Filing Date: December 10, 2003

First Named Inventor: Ilan et al.

Art Unit: 1648

Examiner Name: Emily M. Le

Attorney Docket Number: Enz-64(D1)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city and/or country where published	T ²
	20	Takahashi, M., Nakamura, K., Honda, K., Kitamura, Y., Mitzutani, T., Araki, Y., Kabemura, T., Chijiwa, Y., Harada, N., Nawata, H., "An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis", Dig Dis Sci. 2006 April 51(4): 677-86, (Abstract only)	
	21	Bode, J.G., Ludwig, S., Ehrhardt, C., Albrecht, U., Erhardt, A., Schaper, F., Heinrich, P.C., Haussinger, D., "IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3", FASEB J. 2003 March; 17(3):488-90 Epub 2003 Jan 22.	
	22	Bleicher, P.A., et al., "Expression of murine CD1 on gastrointestinal epithelium," Science 250:679-682 (1990)	
	23	Collins, C., et al., "RAG1, RAG2 and pre-T cell receptor alpha chain expression by adult human hepatic T cells: evidence for extrathymic T cell maturation," Eur. J. Immunol. 26:3114-3118 (1996)	
	24	Madsen, K.L., et al., "Interleukin 10 prevents cytokine-induced disruption of T84 barrier integrity and limits chloride secretion," Gastroenterology 113:151-159 (1997)	
	25	Mitchell, D.G., et al., "Fatty liver. Chemical shift phase-difference and suppression magnetic resonance imaging techniques in animals, phantoms, and humans," Invest. Radiol. 26:1041-1052 (1991)	
	26	Namimoto, T., et al., "Adrenal Masses: Quantification of Fat Content with Double-Echo Chemical Shift In-Phase and Opposed-Phase FLASH MR Images for Differentiation of Adrenal Adenomas," Radiology 218:642-646 (2001)	
	27	Sullards, M.C., et al., "Structure determination of soybean and wheat glucosylceramides by tandem mass spectrometry," J. Mass Spectrometry 35:347-353 (2000);	
	28	Trop, S., et al., "Liver-Associated Lymphocytes Expressing NK1.1 Are Essential for Oral Immune Tolerance Induction in a Murine Model," Hepatology 29:746-755 (1999)	
	29	Vicari, A.P., et al., "Mouse NK1.1+ T cells: a new family of T cells," Immunology Today 17(2):71 (1996)	

/E.L./

06/09/2008

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 5 of 5

Application No. 10/733,489

Filing Date: December 10, 2003

First Named Inventor: Ilan et al.

Art Unit: 1648

Examiner Name: Emily M. Le

Attorney Docket Number: Enz-64(D1)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city and/or country where published	T ²
	30	Smyth et al. (2002) Current Opinion in Immunology. 14: 165-171	
	31	Vliet et al. (1999) Immunology. 98:557-563	
	32	Connolly and Cunningham (2000) European Journal of Anaesthesiology. 17: 219-220.	

/Emily Le/

06/09/2008